TapImmune, Inc. (TPIV)


Other OTC - Other OTC Delayed Price. Currency in USD
0.430.00 (0.00%)
As of 3:57 PM EDT. Market open.
People also watch:
AVXLPPCHSNGXPSIDADXS
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close0.43
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market Cap3.6M
P/E Ratio (ttm)0.10
Beta0.90
Volume0
Avg Vol (3m)194,262
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire13 days ago

    TapImmune Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

    TapImmune Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today that its Board of Directors has approved a 1-for-12 reverse stock split of the Company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The Company believes that it will meet all of the listing requirements for listing the company's common stock on the NASDAQ Capital Market.

  • PR Newswire22 days ago

    MicroCap Review Magazine Fall 2016 Issue Now Available

    LOS ANGELES, Sept. 6, 2016 /PRNewswire/ -- SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, ...

  • PR Newswire22 days ago

    TapImmune Issues Update: Multiple Phase 2 Trials, over $9 Million in New Funding & NASDAQ Uplisting Application

    TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts. Based on the strength of our cancer vaccine technology, we have established collaborations with some of the top medical, biopharmaceutical, and governmental organizations in the world. Also, the U.S. Food and Drug Administration (FDA) has granted TPIV 200 Fast Track designation and Orphan Drug status.